Three years after the U.S. FDA approval of Abbott Laboratories’ Amplatzer Amulet, results of its investigational device exemption trial failed to notably differentiate Abbott’s left atrial appendage ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

In a report released on November 15, David Rescott from Robert W. Baird maintained a Buy rating on Boston Scientific (BSX – Research Report), ...

Health care and tech innovation go hand in hand. From delivering steady streams of medication to speeding up treatment of ...

The "Surgical Microscopes - Market Insights, Competitive Landscape, Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.The surgical microscopes market was valued at USD 1.02 ...

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

Abbott has reported late-breaking five-year positive data from a trial of its Amplatzer Amulet left atrial appendage (LAA) ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

Boston Scientific (BSX) stock climbed 5% after a study showed its Watchman FLX device was superior to oral anti-coagulants in reducing bleeding risks following cardiac ablation.

MedAware, an AI platform improving patient safety, demonstrates the shift from rule-based systems to data-driven, ...